Currently, the most common ways of detecting bladder cancer are cystoscopies and urine cytology tests. The former are costly, invasive, and heavily reliant on how the operator performs them, while the latter are not very effective at detecting cancer in its early stages.
Additionally, cytology tests are prone to error, as they are not the best tool for telling the difference between inflammation and malignancy.
So, in a quest to find a better way of diagnosing bladder cancer, Spain-based researchers from the Polytechnic University of Valencia (UPV), the La Fe Health Research Institute (IIS-La Fe) in Valencia, and the Centre for Biomedical Research in the fields of Bioengineering, Biomaterials and Nanomedicine in Madrid set out to develop a non-invasive method that harnessed the power of ‘taste-detecting’ sensors.
Electronic tongues are a voltammetric device that can ‘mimic’ the mechanism of human taste by using pattern-information software and sensors that can detect soluble compounds.
Scientists use the device to analyse food, water, wine, or explosives, but they can also use it to test samples of biofluid to detect diseases.
The researchers presented the application of electronic tongues for detecting bladder cancer at the XIII International Workshop on Sensors and Molecular Recognition, which took place in the Higher Technical Design Engineering School in Valencia.
Device useful for diagnosing and monitoring
For this new research, the scientists built on previous studies that revealed metabolic differences in the urine of people who had bladder cancer.
These previous studies used established metabolomic techniques, such as liquid chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy, to look at the metabolic profiles both before and after surgery.
The researchers suggest that using electronic tongues to test these urine samples may prove to be a cheap and easy-to-use technique for detecting bladder cancer in its earliest stages.
“There are several trials that have received the approval of the FDA — Food and Drug Administration of the United States — for their use in the diagnosis and monitoring of bladder cancer, but none of them improves the results of a cystoscopy,” explains Javier Monreal, one of the authors of the project and a doctoral researcher at the UPV.
Carmen Martínez Bisbal, also a co-author on the project, says, “The preliminary results of this study, with a 75% accuracy rate, indicate that the shapes of current waveforms induced in urine through pulse voltammetry could allow, with an appropriate processing of the data, for a non-invasive diagnosis in the monitoring of patients with bladder cancer.”
Bladder cancer has a high relapse rate, which is why monitoring patients is particularly important.
In 2012, bladder cancer was the ninth most common malignancy worldwide, with 430,000 newly diagnosed cases.
Source: Medical News Today